Pfizer Limited (BOM:500680)
India · Delayed Price · Currency is INR 5,034.45
-94.60 (-1.84%)
At close: Feb 13, 2026
Pfizer Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 24,823 | 22,814 | 21,932 | 24,248 | 26,110 | 22,386 |
Other Revenue | - | - | - | - | - | 18.2 |
Revenue | 24,823 | 22,814 | 21,932 | 24,248 | 26,110 | 22,404 |
Revenue Growth (YoY) | 11.01% | 4.02% | -9.55% | -7.13% | 16.54% | 4.12% |
Cost of Revenue | 8,718 | 8,158 | 7,983 | 8,778 | 9,529 | 8,028 |
Gross Profit | 16,105 | 14,655 | 13,949 | 15,469 | 16,581 | 14,376 |
Selling, General & Admin | 4,313 | 4,289 | 4,337 | 3,935 | 4,784 | 4,266 |
Other Operating Expenses | 2,819 | 2,947 | 3,219 | 3,434 | 3,425 | 2,971 |
Operating Expenses | 7,725 | 7,844 | 8,179 | 8,423 | 9,359 | 8,330 |
Operating Income | 8,380 | 6,812 | 5,770 | 7,046 | 7,222 | 6,045 |
Interest Expense | -100.6 | -84.1 | -154.1 | -133.9 | -104.9 | -151.1 |
Interest & Investment Income | 1,573 | 1,573 | 1,716 | 854.9 | 489.4 | 369.2 |
Currency Exchange Gain (Loss) | -2.1 | -2.1 | -9.5 | -12.4 | -15 | 5.1 |
Other Non Operating Income (Expenses) | 338.8 | 143.2 | 83.4 | 72.7 | 76.3 | 73.1 |
EBT Excluding Unusual Items | 10,189 | 8,442 | 7,406 | 7,827 | 7,668 | 6,342 |
Merger & Restructuring Charges | -395.8 | - | - | -1,363 | - | 243.6 |
Gain (Loss) on Sale of Assets | -15.3 | -15.3 | -30.5 | 0.5 | 45.8 | 33.3 |
Legal Settlements | - | - | 79.5 | - | - | - |
Other Unusual Items | 1,546 | 1,733 | 0.2 | 1,739 | 12.3 | 57 |
Pretax Income | 11,327 | 10,161 | 7,461 | 8,240 | 7,729 | 6,687 |
Income Tax Expense | 2,791 | 2,485 | 1,947 | 2,001 | 1,603 | 1,711 |
Net Income | 8,536 | 7,676 | 5,513 | 6,239 | 6,126 | 4,976 |
Net Income to Common | 8,536 | 7,676 | 5,513 | 6,239 | 6,126 | 4,976 |
Net Income Growth | 38.67% | 39.23% | -11.64% | 1.86% | 23.10% | -2.26% |
Shares Outstanding (Basic) | 46 | 46 | 46 | 46 | 46 | 46 |
Shares Outstanding (Diluted) | 46 | 46 | 46 | 46 | 46 | 46 |
Shares Change (YoY) | -0.02% | - | -0.01% | - | - | - |
EPS (Basic) | 186.59 | 167.79 | 120.52 | 136.38 | 133.89 | 108.77 |
EPS (Diluted) | 186.59 | 167.79 | 120.52 | 136.38 | 133.89 | 108.77 |
EPS Growth | 38.70% | 39.23% | -11.63% | 1.86% | 23.10% | -2.26% |
Free Cash Flow | - | 6,316 | 2,379 | 2,907 | 6,518 | 4,096 |
Free Cash Flow Per Share | - | 138.06 | 52.01 | 63.54 | 142.46 | 89.54 |
Dividend Per Share | - | 35.000 | 35.000 | 35.000 | 35.000 | 30.000 |
Dividend Growth | - | - | - | - | 16.67% | 200.00% |
Gross Margin | 64.88% | 64.24% | 63.60% | 63.80% | 63.51% | 64.17% |
Operating Margin | 33.76% | 29.86% | 26.31% | 29.06% | 27.66% | 26.98% |
Profit Margin | 34.38% | 33.65% | 25.14% | 25.73% | 23.46% | 22.21% |
Free Cash Flow Margin | - | 27.68% | 10.85% | 11.99% | 24.96% | 18.28% |
EBITDA | 8,639 | 7,052 | 5,985 | 7,704 | 7,879 | 6,697 |
EBITDA Margin | 34.80% | 30.91% | 27.29% | 31.77% | 30.18% | 29.89% |
D&A For EBITDA | 258.33 | 239.8 | 215.1 | 658.5 | 656.8 | 652.1 |
EBIT | 8,380 | 6,812 | 5,770 | 7,046 | 7,222 | 6,045 |
EBIT Margin | 33.76% | 29.86% | 26.31% | 29.06% | 27.66% | 26.98% |
Effective Tax Rate | 24.64% | 24.46% | 26.10% | 24.28% | 20.74% | 25.59% |
Revenue as Reported | 26,741 | 24,536 | 23,737 | 25,258 | 26,736 | 23,197 |
Advertising Expenses | - | 567.5 | 855.9 | 615.9 | 743.8 | 650.2 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.